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Purpose: To evaluate the incidence, severity, and factors related to drug-induced keratoepithe-
liopathy in eyes using antiglaucoma eye drops.
Patients and methods: In a cross-sectional study, 749 eyes from 427 patients who had 
used one or more antiglaucoma eye drops were examined at Niigata University Medical and 
Dental Hospital or related facilities. The incidence and severity of superficial punctate keratitis 
(SPK), patient gender and age, type of glaucoma, and type of eye drops were recorded. SPK 
was graded according to the AD (A, area; D, density) classification. The severity score (SS) 
was calculated from A × D.
Results: SPK was observed in 382 (51.0%) of 749 eyes that had received any type of 
antiglaucoma eye drops. While 254 eyes (33.9%) were classified as A1D1 (SS 1), 34 eyes (4.6%) 
had severe SPK with SS 4 or more. The number of eye drops and the total dosing frequency 
per day were significantly greater in SPK-positive eyes than in eyes without SPK. The number 
of eye drops was proportional to the frequency and severity of SPK. Among eyes that were 
treated with three or more eye drops, SPK was more severe and more frequent in older patients 
(71 years). In addition, a considerable difference was detected for each type of glaucoma.
Conclusion: Drug-induced keratoepitheliopathy is often observed in eyes that have received 
recent antiglaucoma eye drops. The number of eye drops, the total dose frequency per day, patient 
age, and type of glaucoma may affect this condition. We have to consider not only the effects 
on intraocular pressure but also the incidence and severity of drug-induced keratoepitheliopathy 
as a frequent side effect of glaucoma medications.
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Introduction
Almost 10 years have passed since prostaglandin analogs1–5 and topical carbonic 
anhydrase inhibitors6–8 became available as expanded glaucoma medical options, even 
in Japan. Later, α1 or α1β blockers were introduced as treatments with alternative 
hypotensive mechanisms. Timolol eye drops in gel-like formulations9 and long-acting 
carteolol were introduced as daily medications. Suspension-type eye drops8 reduced 
irritation at the time of application. Furthermore, preservative- or benzalkonium 
chloride (BAC)-free eye drops have become available to reduce the influence of eye 
drops on the ocular surface.4,5,10–12 Because of these advances, we can now choose 
from many antiglaucomatous eye drops in various forms with different mechanisms, 
and determine the ones that are most suitable for each patient. It is important for 
glaucoma management to increase treatment efficacy and adherence. We compared 
the average follow-up intraocular pressure (IOP) from 10 years ago to those of recent Clinical Ophthalmology 2010:4 204
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years in patients with primary open-angle glaucoma (POAG) 
or normal tension glaucoma (NTG). The recent follow-up 
IOP was significantly lower than the IOP 10 years ago. This 
reduction was dependent on medical therapy and not surgical 
therapy. The medical therapy for IOP reduction, which is the 
primary goal of glaucoma treatment, has greatly improved 
over the last 10 years.
However, drug interactions and side effects have not 
been satisfactorily evaluated for many antiglaucoma eye 
drops. Topical medication is a very specific treatment in 
ophthalmological clinical practice. Eye drops have a num-
ber of influences that can harm the ocular surface. Because 
the volume of one drop is too much for the conjunctival 
sac, tear components including electrolytes, proteins, and 
mucin must be removed from the tear film.13 These drops 
can also alter ocular pH and osmotic pressure. Furthermore, 
eye drops are known to inhibit the proliferation, regenera-
tion, and turnover of the corneal epithelium.13 Eye drops 
are composed of the active drug as well as preservatives 
and a buffer solution. BAC has been frequently used as a 
preservative in eye drops for many years.13–16 BAC is easily 
solubilized in water and is easy to handle. Because BAC 
has strong antibacterial activity, these eye drops can be safe 
for a long time period. However, BAC is highly toxic to the 
normal corneal epithelium and is closely associated with 
drug-induced keratoepitheliopathy and allergic conjunciti-
vis or blepharitis.14–16 Drug-induced keratoepitheliopathy is 
probably the most frequent and unavoidable side effect of 
glaucoma medications.14–30 However, treatment for chronic 
glaucomas, including POAG and NTG, requires that eye 
drops are applied for a lifetime. In cases of secondary 
glaucoma, multiple eye drops are often used simultane-
ously. Many clinical18–23 and experimental24–27 studies have 
examined drug-induced keratoepitheliopathy. In particular, 
a number of studies have examined the effects of timo-
lol maleate, when used as the first choice for long-term 
glaucoma treatment.20–22 However, most previous reports 
evaluated drug-induced keratoepitheliopathy for each drug, 
and not the multiple drug combinations that are used in 
clinical practice. Only Inoue et al23 reported that multiple 
antiglaucoma eye drops, including a prostaglandin analog 
and a carbonic anhydrase inhibitor, were associated with 
keratoepitheliopathy and ocular factors.
Therefore, we examined the incidence, severity, and 
factors related to drug-induced keratoepitheliopathy in 
clinical practice. The primary aim of this study was to clarify 
the circumstances of drug-induced keratoepitheliopathy 
using a combination of more recent antiglaucoma eye drops. 
In addition, we discuss how to reduce and determine the 
acceptable side effects for long-term glaucoma treatment.
Patients and methods
This study is a practise-based, cross-sectional, observational 
study. The patients included in this study had some type of 
glaucoma and were using one or more antiglaucoma eye 
drops. The patients were followed up at the Niigata University 
Medical and Dental Hospital or related facilities. Ten oph-
thalmologists randomly collected patients at each clinic for 
approximately four weeks starting in mid-April of 2008. The 
total number of cases included 749 eyes from 427 patients.
Keratoepitheliopathy was detected using a fluorescein-based 
staining method. Prior to any ophthalmological examination 
or treatment, including topical anesthesia, the patient’s cornea 
was stained using fluorescein paper (Shouwa Yakuhin Co., 
Tokyo, Japan) and then examined after at least 10 seconds. 
Superficial punctate keratitis (SPK) was detected in each eye 
and the severity was determined by slit lamp examination. 
In this study, even very mild SPK was considered positive. 
Using a check list, we recorded patient gender, age, type of 
glaucoma, eye(s) affected, SPK and its severity, total number 
of eye drops, total dose frequency per day for glaucoma, and 
other disorders. Only preservative-free tear-like eye drops 
were excluded when counting the number of eye drops used 
per day and the dose frequency per day. SPK was classified 
according to the AD classification devised by Miyata et al31 
The severity score (SS) was calculated as A × D.
Seven hundred forty-nine eyes from 427 cases (both eyes 
in 322 cases and one eye in 105 cases) were included in this 
study. The average age was 69.1 ± 12.2 years (± standard 
deviation, 27-94 years). While 335 eyes in 198 cases were 
in male patients, 414 eyes in 229 cases were from females. 
POAG including NTG was diagnosed in 566 eyes, ocular 
hypertension in 14 eyes, primary angle closure or glaucoma 
in 40 eyes, pseudoexfoliation glaucoma (XFG) in 52 eyes, 
glaucoma with uveitis or iridocyclitis in 22 eyes, neovascular 
glaucoma (NVG) in 15 eyes, and other conditions in 40 
eyes. Clinical diagnosis of each glaucoma type was basically 
according to guidelines from the European Glaucoma 
Society32 and the Japan Glaucoma Society.33
Statistical analysis
For statistical analysis, a nonparametric Mann–Whitney 
U-test, was used for the average SS, number of eye drops, 
and total dose frequency per day, because these parameters 
do not follow a normal distribution. The incidence of SPK 
was analyzed by Chi-square test.Clinical Ophthalmology 2010:4 205
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Results
In our study patients, only SPK presented as drug-induced 
keratoepitheliopathy. SPK was detected in 382 (51.0%) of 
749 eyes. Both the average number of eye drops and the 
average total frequency of doses per day were significantly 
greater in eyes with SPK than those without SPK by 
Mann–Whitney U-test (Table 1).
The results are presented in Table 2 by the AD 
classification. While 254 eyes (33.9% of the total and 66.5% 
of SPK-positive) were classified as A1D1 (SS 1), 34 eyes 
(4.6%) had severe SPK with an SS of 4 or more. Figure 1 
shows the severity scores by the number of eye drops. SPK 
was positive in 128 of 348 eyes (36.2%) that used eye drops. 
SPK was positive in 167 of 284 eyes (58.8%) with two, in 
74 of 103 eyes (72.8%) with three, and in all eyes (14 total, 
100%) with four or five eye drops. The frequency of eyes 
with an SS of 2 or more was 8.6% with one eye drop, 18.7% 
with two drops, 35.9% with three eye drops and 57.1% with 
four or five eye drops. As the number of eye drops increased, 
SPK became more frequent and severe. The incidence and SS 
value were not different between male and female patients 
by Chi-square and Mann–Whitney U-tests.
The incidence, average SS, number of eye drops, and 
total dose frequency per day by age group are shown in 
Table 3. When the patients were separated into younger 
(70 years) and older (71 years) groups, incidence (Chi-
square test, P = 0.0031) and severity (SS, Mann–Whitney 
U-test, P  0.0001) were significantly greater in the older 
age group. Similarly, there were significant differences in the 
number of eye drops (Mann–Whitney U-test, P  0.0001) 
and the total frequency per day (Mann–Whitney U-test, 
P  0.0001). Next, we evaluated differences between the 
younger and older age groups based on the number of eye 
drops (Table 4). The incidence and severity were quite simi-
lar between the two age groups in eyes using only one eye 
drop. However, SPK tended to occur more frequently and 
severely in eyes with two eye drops, although this was not 
statistically significant. Finally, the incidence and severity 
were significantly greater in the older age group in eyes 
with three or more eye drops compared with the younger 
age group.
Table 5 summarizes the number of eyes, average age, 
incidence and severity of SPK, number of eye drops, and total 
dose frequency per day for each type of glaucoma.
Discussion
In this study, almost half of the eyes using antiglaucoma eye 
drops previously had SPK with varying severities (Table 1). 
Two hundred fifty-four eyes (33.9% of total and 66.5% of 
SPK-positive eyes) had only faint to mild SPK with an SS 
of 1 (A1D1). Severe SPK was detected in 18 eyes (2.4% of 
total) classified as SS 6 and in two eyes (0.3% of total) with 
SS 9 (Table 2). While the majority of cases of drug-induced 
keratoepitheliopathy had only mild SPK, there were a few 
severe cases associated with glaucomatous medication.23
Miyata et al31 evaluated the severity of SPK on a scale 
from 0 to 6 with values based on A + D. They reported that 
the fluorescein concentration in the cornea increased on a 
scale of 0 to 6 in a manner similar to a quadratic function. 
Therefore, we thought that a scale for evaluating the severity 
of SPK based on values of A × D may be more suitable than 
one using values of A + D, particularly for more severe cases. 
The incidence or severity of drug-induced keratoepitheliopa-
thy was closely related to the number of eye drops or total 
dosing frequency per day as shown in Figures 1 and 2. The 
more eye drops that were used, the more frequent and more 
severe the SPK. In particular, all eyes that received four or 
more eye drops had combined SPK. Similar relationships 
can be seen between the incidence, severity, and total dose 
frequency per day. Both ophthalmologists and glaucomatous 
patients may have to tolerate faint to mild side effects in order 
to continue these medications because of the characteristics 
of glaucoma treatment. Mild SPK without any related sub-
jective symptoms, such as foreign body sensation, irritation, 
or blurred vision may be permissible. Mild SPK means that 
within an SS of 1, the following percentage of eyes would 
Table 1 The incidence of drug-induced SPK
SPK Number of eyes Number of eye drops P1 Total dose frequency per day P1
(-) 367 (49.0%) 1.446 ± 0.617 (1–3) 0.0001 2.274 ± 1.624 (1–10) 0.0001
(+) 382 (51.0%) 1.945 ± 0.896 (1–5) 3.622 ± 2.442 (1–14)
Note: 1By the Mann–Whitney U-test.
Abbreviation: SPK, superficial punctate keratitis.
Table 2 The number of eyes from the AD classification
A1 A2 A3
D1 254 (33.9%) 39 (5.2%) 20 (2.7%)
D2 32 (4.3%) 14 (1.9%) 12 (1.7%)
D3 3 (0.4%) 5 (0.7%) 2 (0.3%)Clinical Ophthalmology 2010:4 206
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be worse than the tolerated level: 8.6% of eyes with one eye 
drop, 18.7% with two, 35.9% with three, and 57.1% with 
four or five eye drops.
Drug-induced keratoepitheliopathy is thought to be 
closely related to age because tear secretion decreases34 and 
the epithelial proliferative activity changes with age.13 In this 
study, eyes in the older age group had more frequent and 
severe SPK (Table 4). However, the number of eye drops and 
total dose frequency per day were also related to severity of 
SPK. Thus, we evaluated patients based on the number of eye 
drops and their age (over or under age 70 years). Although 
the incidence and severity were similar in the eyes using only 
one eye drop, eyes that received two eye drops had more fre-
quent and severe SPK in the older age group, although these 
increases were not statistically significant. Finally, the older 
age group using three or more eye drops showed a statisti-
cally significant difference (Table 5). As with the number 
of eye drops, advancing age may increase the likelihood of 
drug-induced keratoepitheliopathy.
In addition, a considerable difference was detected based 
on the type of glaucoma. We compared them with open angle 
glaucoma (OAG, including POAG and NTG), which is a basic 
type of glaucoma. The eyes with ocular hypertension tended to 
use fewer eye drops and to have less combined SPK. In pseu-
doexfoliation glaucoma, the incidence and severity as well as 
the number of eye drops were increased compared with those 
in OAG. Eyes with primary angle-closure glaucoma had more 
frequent and severe SPK, although the number of eye drops 
and total dose frequency per day were similar with OAG. 
However, the reasons for these differences are unknown. 
Eyes with uveitis had more SPK when more than one eye 
drop was used, and 3- to 4-fold higher total dose frequencies, 
compared with OAG, probably because one or more steroid or 
non-steroid eye drops were used to treat uveitis. While eyes 
with neovascular glaucoma used fewer eye drops than those 
with uveitis, SPK was remarkably more frequent and severe. 
Almost all cases of NVG had combined proliferative diabetic 
retinopathy as well as diabetic keratopathy. Therefore, the 
corneal epithelium with NVG appears to be easier to injure 
but harder to improve. Specific differences in drug-induced 
keratoepitheliopathy may depend on specific treatments for 
each type of glaucoma.
The general incidence of SPK was reported to be 1% 
to 2%, based on clinical trials for antiglaucomatous eye 
drops. These findings raise the question of why SPK has 
been commonly reported in clinical practice. Although 
glaucomatous patients increase with age, patients in the older 
age group are usually excluded from clinical trials. Only one 
eye drop is usually given in clinical trials, or two at most for 
post-marketing surveillance purposes. Furthermore, clinical 
trials set a washout period (usually one month) before 
starting eye drop therapy. If the subjects had SPK when using 
antiglaucomatous eye drops, SPK should have disappeared 
during one month without medication. Without eye drops, 
the condition of the ocular surface, including the corneal 
epithelium and tear film, must have improved and become 
resistant to eye drops for several weeks to months. In clinical 
practice, many glaucomatous patients have to continue using 
one or more eye drops for long time periods, basically for a 
lifetime in the case of POAG or NTG patients. These patients 
often belong to the older age group. Thus, the background of 
drug-induced keratoepitheliopathy must be much more severe 
and difficult to improve in clinical practice than in clinical 
trials. In this study, we also recorded which drugs were used 
for specific eyes. Instead of the number of eye drops, the types 
Table 3 Age groups and the incidence of SPK
Age Eyes SPK (+) Severity (SS) Number of eye drops Total dose frequency per day
-50 67 41 (61.2%) 0.784 ± 0.893 1.769 ± 0.632 3.108 ± 1.913
51–60 109 44 (40.2%) 0.691 ± 1.260 1.710 ± 0.858 2.784 ± 2.172
61–70 193 83 (43.0%) 0.686 ± 1.034 1.567 ± 0.721 2.432 ± 1.874
71–80 251 140 (55.8%) 1.107 ± 1.562 1.756 ± 0.830 3.186 ± 2.487
81- 129 72 (55.8%) 0.858 ± 1.081 1.819 ± 0.826 3.614 ± 2.591
Abbreviations: SPK, superficial punctate keratitis; SS, severity score.
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Figure 1 The number of eyedrops and SPK severity score (SS). 
Abbreviation: SPK, superficial punctate keratitis.Clinical Ophthalmology 2010:4 207
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of eye drops or the combinations of eye drops may affect the 
incidence and severity of keratoepitheliopathy. We intend to 
examine these possibilities in the near future.
Faint to mild side effects such as keratoepitheliopathy 
need to be tolerable with glaucomatous treatment. However, 
we have to avoid or minimize these side effects as much as 
possible, even if patients are not aware of them. For example, 
among eye drops that have similar efficacy in reducing IOP, 
we should select glaucomatous eye drops that are the safest 
for the ocular surface. For older patients who have mild visual 
field defects, we recommend that their first glaucomatous eye 
drop is chosen from ones that are safe and/or have mild effects 
on the ocular surface. When moderate to severe drug-induced 
keratoepitheliopathy is discovered, we would first suggest 
changing the eye drops. However, these conditions are often 
hard to improve because they have different backgrounds, 
such as dry eyes and Meibomian gland dysfunction. We have 
to consider seriously suspending aggressive treatments with 
eye drops. Using only preservative-free tear eye drops might 
normalize the conditions of the ocular surface, tear film, and 
corneal epithelium after a period of time. After that, we can try 
individual eye drops that are safer for the cornea. Finally, we 
have to perform glaucoma surgery instead of medicating in 
severe cases of drug-induced keratoepitheliopathy.
As a general concept, drug-induced keratoepitheliopathy 
results from a combination of the active drug and the vehicle, 
including preservatives and additives.10–30 In particular, 
BAC is a preservative that is toxic to the cornea.13–16 
Recently, some eye drops without preservatives or BAC 
have become available for glaucomatous treatment.4,10–12 
While preservative-free glaucomatous eye drops have been 
introduced using small unit-dose bottles,4 a membrane filter 
can be set on the top of the bottle to make some glaucomatous 
eye drops preservative-free.11,12 In addition, there are other 
glaucomatous eye drops that use non-BAC preservatives.4,5,35 
BAC can actually injure the barrier function of the corneal 
epithelium.13 While this might relate to the corneal epithelial 
damage caused by BAC, it also might make the eye drops 
penetrate further into the eye through the cornea. Some 
previous reports have confirmed the benefits of BAC-free 
antiglaucoma eye drops.4,5,10–12,24,25 Ishibashi et al24 reported 
that preservative-free timolol did not reduce non-invasive 
breakup time. On the other hand, anti-glaucoma eye drops 
without BAC may have weaker effects on IOP reduction than 
Table 5 Diagnosis of glaucoma and the incidence of SPK
Dx Eyes Age SPK (+) Severity (SS) Number of eye drops Total dose frequency 
per day
OAG 565 69.0 ± 12.1 274 (48.5%) 0.759 ± 1.107 1.681 ± 0.779 2.877 ± 2.283
XFG 52 76.1 ± 6.9 30 (57.7%) 1.000 ± 1.278 1.860 ± 0.728 2.220 ± 1.844
PAC/G 40 73.8 ± 8.1 27 (67.5%)* 1.410 ± 1.585# 1.641 ± 0.778 3.000 ± 2.284
Uveitis 22 63.9 ± 14.5 16 (72.7%)*   1.772 ± 1.998# 2.500 ± 1.225# 6.180 ± 4.283#
OH 20 65.4 ± 15.9 6 (31.5%) 0.400 ± 0.754 1.200 ± 0.410# 2.250 ± 1.112*
NVG 15 68.5 ± 11.0 14 (93.3%)# 2.500 ± 2.653# 2.285 ± 0.825# 4.929 ± 2.056# 
Notes: *P  0.05, #P  0.01 against for OAG.
Abbreviations: OAG, Primary open-angle glaucoma with normal tension glaucoma; XFG, Pseudoexfoliation glaucoma; PAC/G, Primary angle-closure or primary angle-closure 
glaucoma; Uveitis, Glaucoma with uveitis or iridocyclitis; OH, Ocular hypertension; NVG, Neovascular glaucoma; SPK, superficial punctate keratitis.
Table 4 SPK by the number of eye drops and age groups
Number of eye drops Age group eyes SPK (+) P1 Severity (SS) P2
1  70-year-old 187 70 (37.4%) 0.7381 0.459 ± 0.684 0.9892
 71-year-old 161 57 (35.4%) 0.510 ± 0.860
2  70-year-old 129 68 (52.7%) 0.0904 0.875 ± 1.316 0.0704
 71-year-old 155 98 (63.2%) 1.077 ± 1.297
3  70-year-old 45 25 (56.6%) 0.0018 1.159 ± 1.509 0.0106
 71-year-old 58 49 (84.5%) 1.948 ± 1.959
Notes:  1By the chi-square test. 2By Mann–Whitney U-test.
Abbreviation: SPK, superficial punctate keratitis.Clinical Ophthalmology 2010:4 208
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those with BAC. For travoprost, the ability to reduce IOP was 
quite similar with and without BAC.4,5
A limitation of this study was that we did not confirm 
the incidence of SPK in glaucomatous patients without eye 
drops. This is supposed to be about 10%, but these patients 
are not typical glaucomatous cases. Because they often 
had histories of glaucoma surgery or very mild visual field 
defects, it was not necessary to apply eye drops to treat 
glaucoma. Another limitation was that we examined each 
eye only once within the study period. With repeated exami-
nations, SPK often appears and disappears by chance, even 
in the same eye. Drug-induced keratoepitheliopathy may 
also be influenced by seasonal or regional differences. Dry 
eye, Meibomian gland dysfunction, or a history of ocular 
surgeries might also relate to these conditions as background 
complications. Further studies are warranted that include 
these conditions.
Drug-induced keratoepitheliopathy may be more frequently 
observed after treatment with antiglaucomatous medication. 
The number of eye drops, the total dose frequency per day, age 
of the patient, and type of glaucoma might relate to this condi-
tion. We have to consider not only their effects on IOP, but also 
the incidence and severity of drug-induced keratoepitheliopathy 
as the most frequent side effect of glaucoma medication. In 
particular, careful observation is needed for the eyes that are 
treated with multiple eye drops in older age groups.
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